Zheng Ju-Yan, Liu Jun-Yan, Zhu Tao, Liu Chong, Gao Ying, Dai Wen-Ting, Zhuo Wei, Mao Xiao-Yuan, He Bai-Mei, Liu Zhao-Qian
Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Institute of Clinical Pharmacology, Central South University, Changsha, China.
Front Pharmacol. 2022 Jul 18;13:895608. doi: 10.3389/fphar.2022.895608. eCollection 2022.
Hepatocellular carcinoma (HCC) is a common and deadly malignancy worldwide. Current treatment methods for hepatocellular carcinoma have many disadvantages; thus, it is urgent to improve the efficacy of these therapies. Glycolysis is critical in the occurrence and development of tumors. However, survival and prognosis biomarkers related to glycolysis in HCC patients remain to be fully identified. Glycolysis-related genes (GRGs) were downloaded from "The Molecular Signatures Database" (MSigDB), and the mRNA expression profiles and clinical information of HCC patients were obtained from TCGA. Consensus clustering was performed to classify the HCC patients into two subgroups. We used the least absolute shrinkage and selection operator (LASSO) regression analysis to construct the risk signature model. Kaplan-Meier (K-M) survival analysis was performed to evaluate the prognostic significance of the risk model, and the receiver operating characteristic (ROC) curve analysis was used to evaluate the prediction accuracy. The independent prediction ability of the risk model was validated by univariate and multivariate Cox regression analyses. The differences of immune infiltrates and relevant oncogenic signaling between different risk groups were compared. Finally, biological experiments were performed to explore the functions of screened genes. HCC patients were classified into two subgroups, according to the expression of prognostic-related GRGs. Almost all GRGs categorized in cluster 2 showed upregulated expressions, whereas GRGs in cluster 1 conferred survival advantages. GSEA identified a positive correlation between cluster 2 and the glycolysis process. Ten genes were selected for risk signature construction. Patients were assigned to high-risk and low-risk groups based on the median risk score, and K-M survival analysis indicated that the high-risk group had a shorter survival time. Additionally, the risk gene signature can partially affect immune infiltrates within the HCC microenvironment, and many oncogenic pathways were enriched in the high-risk group, including glycolysis, hypoxia, and DNA repair. Finally, knockdown of ME1 suppressed proliferation, migration, and invasion of hepatocellular carcinoma cells. In our study, we successfully constructed and verified a novel glycolysis-related risk signature for HCC prognosis prediction, which is meaningful for classifying HCC patients and offers potential targets for the treatment of hepatocellular carcinoma.
肝细胞癌(HCC)是全球范围内常见且致命的恶性肿瘤。目前肝细胞癌的治疗方法存在诸多弊端;因此,提高这些疗法的疗效迫在眉睫。糖酵解在肿瘤的发生发展中至关重要。然而,HCC患者中与糖酵解相关的生存和预后生物标志物仍有待充分确定。从“分子特征数据库”(MSigDB)下载糖酵解相关基因(GRGs),并从TCGA获取HCC患者的mRNA表达谱和临床信息。进行一致性聚类将HCC患者分为两个亚组。我们使用最小绝对收缩和选择算子(LASSO)回归分析构建风险特征模型。进行Kaplan-Meier(K-M)生存分析以评估风险模型的预后意义,并使用受试者工作特征(ROC)曲线分析评估预测准确性。通过单变量和多变量Cox回归分析验证风险模型的独立预测能力。比较不同风险组之间免疫浸润和相关致癌信号的差异。最后,进行生物学实验以探索筛选出的基因的功能。根据预后相关GRGs的表达,HCC患者被分为两个亚组。几乎所有归类于簇2的GRGs均表现为上调表达,而簇1中的GRGs赋予生存优势。基因集富集分析(GSEA)确定簇2与糖酵解过程之间呈正相关。选择10个基因构建风险特征。根据中位风险评分将患者分为高风险和低风险组,K-M生存分析表明高风险组的生存时间较短。此外,风险基因特征可部分影响HCC微环境中的免疫浸润,并且许多致癌途径在高风险组中富集,包括糖酵解、缺氧和DNA修复。最后,敲低ME1可抑制肝癌细胞的增殖、迁移和侵袭。在我们的研究中,我们成功构建并验证了一种用于HCC预后预测的新型糖酵解相关风险特征,这对于HCC患者的分类具有重要意义,并为肝细胞癌的治疗提供了潜在靶点。